On an annual basis, states are required to report on their practitioners prescribing habits, cost savings generated from their Drug Utilization Review (DUR) programs and their program’s operations, including adoption of new innovative DUR practices via the Medicaid Drug Utilization Review Annual Report Survey. Please visit the Drug Utilization Review page for more information.
For an overview of Medicaid Prescription Drug Programs visit the Prescription Drugs page.
National State Comparison/Summary Report
|2019||FFS||State Comparison Report (PDF, 23.15 MB)|
|2019||MCO||State Comparison Report (PDF, 8.5 MB)|
|2018||FFS||State Comparison Report (PDF, 4.02 MB)|
|2018||MCO||State Comparison Report (PDF, 4.61 MB)|
|2017||FFS||State Comparison Report (PDF, 1.03 MB)|
|2016||FFS||State Comparison/Summary Report (PDF, 830.38 KB)|
|2015||FFS||State Comparison/Summary Report (PDF, 841.05 KB)|
|2014||FFS||State Comparison/Summary Report (PDF, 1.22 MB)|
|2013||FFS||State Comparison/Summary Report (PDF, 702.18 KB)|
|2012||FFS||State Comparison/Summary Report (PDF, 337.68 KB)|
42 CFR Subpart K – Drug Use Review (DUR) Program and Electronic Claims Management System for Outpatient Drug Claims Section 456.700-456.725 provides the requirements for the DUR program.
Please direct all communications to the CMSDUR@cms.hhs.gov resource mailbox.